Two current and one former Neoprobe (NYSE Amex:NEOP) executive plan to begin unloading shares of the cancer diagnostics company after the U.S. Food and Drug Administration accepts an application associated with its radiopharmaceutical Lymphoseek. CFO Brent Larson could sell up to 12 percent of his equity in the company, while Roger Brown, vice president of […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) said it had gained clarity around the chemistry and manufacturing of its investigational colorectal cancer detection drug after a meeting with European regulators. Most significantly to Neoprobe, the meeting confirmed the company’s opportunity to develop a humanized antibody rather than a mouse-based antibody in its clinical development of RIGScan, […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In a deal that marks its transformation to a pure-play radiopharmaceutical company, Neoprobe (NYSE Amex:NEOP) has completed the sale of its radiation detection business to Devicor Medical Products. The deal’s value could reach $50 million for Dublin, Ohio-based Neoprobe — $30 million up front and $20 million in royalties if Devicor’s sales of the acquired […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) is continuing to enroll patients in a phase 3 head and neck cancer clinical trial of its radiopharmaceutical Lymphoseek. The trial is aimed at expanding Lymphoseek’s label to cover procedures known as sentinel lymph node biopsies, CEO Mark Pykett said in a conference call with investors. The sentinel lymph […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has filed a New Drug Application for its radiopharmaceutical Lymphoseek. The filing is a key step for the company and has been a long time coming. If the U.S. Food and Drug Administration approves the application, Neoprobe could begin selling the drug, which would represent a huge milestone for […]
Figuring Neoprobe‘s (NYSE Amex:NEOP) stock price has fallen far enough, the hedge fund manager who drew attention for criticizing the company has called off his recommendation to short its shares. Martin Shkreli, CEO of New York-based hedge fund MSMB Capital, said that with Neoprobe hovering slightly above $2, he “cannot in good faith” recommend maintaining […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The short seller who’s driven Neoprobe (NYSE Amex:NEOP) investors crazy is coming under scrutiny from a public ethics group. Citizens for Responsibility and Ethics in Washington (CREW) filed a Freedom of Information Act (FOIA) request that seeks to make public any communications between short seller Martin Shkreli, CEO of New York-based hedge fund MSMB Capital, […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) reported a $2.2 million loss in the second quarter, but with this company the financials rarely tell much of the story. The company’s primary focus is on preparing a New Drug Application (NDA) for its radiopharmaceutical Lymphoseek that, if approved, would give the company the right to begin marketing […]
Neoprobe (NYSE Amex: NEOP) remains on track to file a New Drug Application for its drug used for cancer detection, Lymphoseek, sometime in the third quarter. Factoring in the customary 10-month review period by the U.S. Food and Drug Administration, that would make a decision on the application for the drug used in cancer treatments […]
The hedge fund manager Neoprobe (NYSE Amex: NEOP) investors love to hate isn’t eager to take credit for the cancer diagnostics company’s free-falling stock price. But the fact remains that Dublin, Ohio-based Neoprobe’s shares are down 40 percent since short-seller Martin Shkreli of New York-based MSMB Capital began agitating about his concerns over the design […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has blasted a hedge fund manager’s criticism of its key Lymphoseek clinical trials as “baseless” and inaccurate. The Dublin, Ohio company said MSMB Capital’s complaints about the trial’s design are “baseless and replete with factual and regulatory misstatements, served under a cloak of legitimacy,” according to a statement. Last […]
Life science current events this week include Neoprobe's petition to the FDA to deny approval of Lymphoseek and Arteriocyte's new deal with the Army.
A New York hedge fund has filed a petition with the U.S. Food and Drug Administration to request that the agency deny Neoprobe‘s (NYSE Amex:NEOP) application for approval of its radiopharmaceutical Lymphoseek. In the nine-page (pdf) citizen petition, MSMB Capital says the FDA should deny Neoprobe’s request for a review of Lymphoseek due to what […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has reported the full results of a phase 3 trial of its radiopharmaceutical Lymphoseek. Reiterating earlier reports from when the Dublin, Ohio-based company released top-line data on the trial, Neoprobe said in a statement that the study met all primary and secondary endpoints, and exhibited superior performance to the […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has hired a former Alseres Pharmaceuticals executive as its new chief business officer. Thomas Tulip will help the Dublin, Ohio-based company seek out business opportunities for two radiopharmaceutical drug candidates it has under development and look for partner companies from which Neoprobe can license or acquire future drugs, according […]